Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

In this case report, a nine-year-old child with vitiligo and alopecia areata was successfully treated with upadacitinib and UVB, resulting in a significant reduction in the affected areas, suggesting a promising treatment approach for similar pediatric cases.

This letter discusses a case of iododerma in pregnancy linked to iodinated multivitamin use, but reports no new clinical findings.

In these randomized, placebo-controlled trials, patients with alopecia areata who received baricitinib showed significantly higher eyebrow and eyelash hair regrowth rates compared to placebo, with greater responses observed at the 4 mg dose and in those achieving overall scalp hair improvement by Week 52.

This study found that treatment with ritlecitinib led to significant scalp hair regrowth in patients with alopecia areata at Weeks 24 and 48, with higher response rates observed in those receiving 50 mg compared to 30 mg doses.

In this Italian retrospective study, ritlecitinib 50 mg/day showed effectiveness and good tolerability for treating severe alopecia areata over 24 weeks, achieving significant hair regrowth particularly in adolescents, as well as improvements in eyebrows, eyelashes, nails, and quality of life, with mostly mild adverse effects.

This study found that nanostructured lipid carriers could serve as a promising vehicle for topical Acitretin delivery in psoriasis treatment, potentially reducing oral side effects and enhancing patient compliance.

This research reported that eflornithine HCl 13.9% cream generally has a favorable dermal safety profile for managing unwanted facial hair in women, though it can cause mild irritation under certain conditions.

In this study, patients with alopecia areata who experienced sustained hair regrowth while being treated with baricitinib showed improvements in health-related quality of life and reductions in anxiety and depression symptoms over 104 weeks, according to the BRAVE-AA phase III trials.

Actemra is approved for a specific artery condition, HIV treatment adherence has improved, women may pay more for a hair loss product, and incorrect dosing of blood thinners can be risky.

This study noted that combining oral acitretin with narrowband ultraviolet B therapy may reduce treatment time and dosages for psoriasis, potentially lowering the long-term skin cancer risk.

This review discusses baricitinib's applications for various inflammatory disorders and highlights its promising efficacy alongside potential adverse effects, advocating for further research before it becomes a standard treatment.

Using Excimer light with topical steroids is the most effective treatment for alopecia areata.

This study reports a case of alopecia areata affecting the eyebrow and eyelash in a female patient after starting acitretin therapy for psoriasis.

This case report describes a 6-year-old girl with IFAP syndrome who showed good improvement in cutaneous symptoms after one month of acitretin treatment.

This study found that topical valproate has minimal potential to cause skin irritation, suggesting it can be applied safely to human skin.

In this study, researchers evaluated CS12192, a selective JAK3 inhibitor, in an alopecia areata mouse model and found it reversed hair growth inhibition comparably to baricitinib, with better safety and similar immune-modulating mechanisms.

This CADTH recommendation advises that Olumiant should be publicly reimbursed for treating severe alopecia areata in adults, provided conditions such as a 50% scalp hair loss and specific prescribing criteria are met.

This case report describes a 48-year-old male with severe, itchy hypertrophic lichen planus who showed a 90% improvement in lesions following 4 months of treatment with oral acitretin, with no recurrence 6 months posttreatment.

This study found that alopecia areata patients often had low vitamin D levels, and topical calcipotriol treatment significantly reduced the severity of their hair loss.

This study found that most patients with folliculitis decalvans showed improvement and remission with oral antibiotics, although some experienced relapses and required prolonged treatment.

This review discusses the condition alopecia areata and summarizes its available treatments, mentioning three recently approved Janus kinase inhibitors, but reports no new clinical results.

In this study, the 308-nm excimer lamp was reported to be a safe alternative treatment for alopecia areata, with a 41.1% overall response rate and a 50% response rate in severe cases.

In this study, subcutaneous recombinant human IL-12 showed a 43% partial response rate in early-stage mycosis fungoides patients refractory to previous treatments, with generally mild to moderate adverse events reported.

This study found that treatment with baricitinib 4 mg over 52 weeks led to clinically meaningful regrowth of eyebrows and eyelashes in patients with alopecia areata, even without complete scalp hair regrowth.

This study found that ritlecitinib 50 mg offered a lower cost per responder than baricitinib 2 or 4 mg for treating severe alopecia areata at Weeks 24 and 52, potentially influencing reimbursement decisions.

This study observed that treating acne scars with fractional ablative laser concurrently with isotretinoin improved outcomes more effectively compared to applying the laser 6 months after isotretinoin treatment ended, as measured by the Quantitative Global Acne Scarring Grading System.

This study highlights that while there are no FDA- or ANVISA-approved treatments for children with alopecia areata, JAK inhibitors are emerging as a promising therapeutic option for this population.

This review by Aceituno et al. found that both baricitinib and ritlecitinib demonstrate strong efficacy for severe alopecia areata, with meaningful hair regrowth by Week 24, but notes limitations like differing trial sizes and potential effect size overestimations.

This study evaluated a novel hand-held low-level light therapy device for treating mild-to-moderate acne, finding it significantly reduced inflammatory lesions and moderate acne severity without severe adverse reactions, while also reducing Cutibacterium acnes viability in vitro.